PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Neurochem. Author manuscript; available in PMC 2010 August 1.
Published in final edited form as:
PMCID: PMC2770254
NIHMSID: NIHMS136003

Brain sterol dys-regulation in sporadic AD and MCI: Relationship to heme oxygenase-1

Abstract

The objective of this study was to ascertain the impact of aging and Alzheimer disease (AD) on brain cholesterol (CH), CH precursors and oxysterol homeostasis. Altered CH metabolism and up-regulation of heme oxygenase-1 (HO-1) are characteristic of AD-affected neural tissues. We recently determined that HO-1 over-expression suppresses total CH levels by augmenting liver X receptor-mediated CH efflux and enhances oxysterol formation in cultured astroglia. Lipids and proteins were extracted from post-mortem human frontal cortex derived from subjects with sporadic AD, mild cognitive impairment (MCI) and no cognitive impairment (NCI; n=17 per group) enrolled in the Religious Orders Study, an ongoing clinical-pathologic study of aging and AD. ELISA was used to quantify human HO-1 protein expression from brain tissue and GC-MS to quantify total CH, CH precursors and relevant oxysterols. The relationships of sterol/oxysterol levels to HO-1 protein expression and clinical/demographic variables were determined by multivariable regression and non-parametric statistical analyses. Decreased CH, increased oxysterol and increased CH precursors concentrations in the cortex correlated significantly with HO-1 levels in MCI and AD, but not NCI. Specific oxysterols correlated with disease state, increasing neuropathological burden, neuropsychological impairment and age. A model featuring compensated and de-compensated states of altered sterol homeostasis in MCI and AD are presented based on the current data set and our earlier in vitro work.

Keywords: Lipids, Oxysterols, Cholesterol, Cholesterol Precursors, Heme Oxygenase-1, Religious Order Study, Alzheimer’s disease, Multivariable analysis

Introduction

Alzheimer disease (AD) is an aging-related dementing illness that afflicts approximately 5–10% of North Americans over the age of 65 and approximately 30–50% of those who survive to the end of their ninth decade (Hendrie 1998). AD is characterized by progressive neuronal degeneration, gliosis, and the accumulation of intracellular inclusions (neurofibrillary tangles; NFT) and extracellular deposits of β-amyloid (senile plaques) in discrete regions of the basal forebrain, hippocampus, and association cortices (Selkoe 1991). The role(s) of sterol homeostasis, particularly cholesterol metabolism, is currently the subject of intense interest vis-à-vis the etiopathogenesis of AD. Cholesterol (CH) subserves a variety of biological roles in mammalian tissues and is of particular importance in the central nervous system (CNS), being a major component of cellular membranes and a determinant of membrane fluidity. CH may act as a cell signaling molecule, influence gene transcription, and is an essential precursor of all bioactive steroids. The blood-brain barrier (Bjorkhem & Meaney 2004, Pfrieger 2003) (BBB) is largely impermeable to circulating CH and in the adult CNS CH is synthesized and regulated within glial cells. The astrocytic compartment meets neuronal CH demands by secreting CH-apolipoprotein (APOE) complexes (Bjorkhem & Meaney 2004).

Epidemiological studies have suggested an association between circulating CH and the pathogenesis of AD (Panza et al. 2006, Simons et al. 2001, Shobab et al. 2005). However, this relationship remains largely uncharacterized and ill-defined due to several factors: First, most human studies have correlated peripheral serum or plasma CH levels with the incidence of AD; few have focused on CNS CH which is regulated independently of the peripheral CH pool. Second, most human studies have relied on retrospective epidemiological data which often lack critical subject information germane to both AD and CH homeostasis. This includes factors such as apolipoprotein E4 (APOE4) status, exposure to pharmacological CH lowering agents (e.g. statins), neuropathology scores, neuropsychological testing and disease progression rates, all of which may impact the interpretation of sterol-related findings. Finally, most human studies have emphasized select components of the CH regulatory pathway, rather than evaluating the pathway as a whole. Given the numerous biological factors and conditions which may impact CH and its regulatory mechanisms, there is much to be gained by conducting comprehensive evaluations of the pathways impacting CH levels/turnover within the CNS and determining their relationships to brain aging and AD.

Heme oxygenase-1 (HO-1) is a 32-kDa stress protein that mediates the catabolism of heme to biliverdin, free iron, and carbon monoxide (CO). The ho-1 gene is susceptible to upregulation by a host of noxious stimuli (e.g., β-amyloid, hydrogen peroxide, Th1 cytokines) and is induced in CNS tissues affected by Alzheimer disease, Parkinson disease, and other neurological conditions (Schipper 2004). The up-regulation of HO-1 may confer cytoprotection by enhancing the breakdown of pro-oxidant heme to the radical scavenging bile pigments, biliverdin and bilirubin (Llesuy & Tomaro 1994, Baranano & Snyder 2001, Dore et al. 1999, Nakagami et al. 1993). Under certain conditions, however, heme-derived iron and CO may exacerbate intracellular oxidative stress and substrate damage by provoking free radical generation within mitochondria and other subcellular organelles (Piantadosi et al. 2006). In AD, increased oxidative stress may intensify neurodegeneration, increase lipid peroxidation and engender the formation of oxidized cholesterol (oxysterols) (Arca et al. 2007, Bjorkhem & Diczfalusy 2002), events which may directly or indirectly promote APP processing in favor of insoluble β-amyloid deposition (Nelson & Alkon 2005), tau hyperphosphorylation and NFT formation, mitochondrial insufficiency and neuronal cell death (Melov et al. 2007).

Our laboratory has previously established a link between HO-1 over-expression/overactivity and sterol dys-regulation in cultured astroglia, characterized by suppression of total CH concentrations and increased enzymatic and non-enzymatic oxysterol formation (Vaya et al. 2007). Additionally, we have recently delineated the mechanisms whereby HO-1 mediates these effects on CH homeostasis (Hascalovici et al. 2009). To ascertain the link between HO-1 and altered sterol regulation in aging and AD, we now extend our investigation to post-mortem brain tissues derived from individuals with no cognitive impairment (NCI), mild cognitive impairment (MCI) and AD enrolled in the Religious Orders Study.

Materials and Methods

Post-mortem brain tissue

We evaluated a total of 51 post-mortem brain tissue samples of frontal cortex derived from subjects with sporadic AD, MCI and NCI (n=17 per group). However, low-resolution output from one specimen limited most analyses to a total of 50 subjects. All subjects were older Catholic clergy enrolled in the Religious Orders Study, a longitudinal clinical-pathologic study of aging and AD at Rush University Medical Center (Chicago, IL). Each subject signed an informed consent and an anatomical gift act donating his/her brain to Rush investigators at the time of death. The Religious Order Study was approved by the Institutional Review Board of Rush University Medical Center. Each subject underwent a uniform structured clinical evaluation that included a medical history, neurologic examination, neuropsychological performance testing and review of neuroimaging when available, as previously described (Bennett et al. 2002). The diagnosis of AD was made according to criteria established by the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer’s disease and Related Disorders Association (NINCDS/ADRDA)(McKhann et al. 1984). The diagnosis of MCI refers to persons who are rated as impaired on neuropsychological tests but were not found to have dementia by the examining physician (Bennett et al. 2002). Cognitive function tests were selected to assess a broad range of abilities commonly affected by aging and AD as previously reported (Wilson et al. 2002). Subject information germane to AD and sterol metabolism included clinical diagnoses at the time of death, gender, age, Mini-Mental State Examination (MMSE), years of education, apolipoprotein E genotype, statin exposure (Arvanitakis et al. 2008), time from diagnosis to death, post-mortem interval (PMI) and neuropathology data (Braak staging and classification according to NIA-Regan and CERAD criteria).

Lipid Extraction and Measurements

Tissue preparation

Brain samples were manually homogenized in a solution containing 0.5 ml of phosphate buffered saline (PBS), with 0.45 mmol/L of butylated hydroxytoluene (an antioxidant present throughout the entire workup procedure to obviate tissue oxidation), one protease inhibitor tablet per 10 ml of solution, and 49.6 μmol/L solution of 19-hydroxycholesterol (19-OH) as internal standard. (in 1.5 ml Eppendorf tubes). Samples were transferred to 15 ml conical tubes and PBS was added to each sample to obtain a final volume of 2 ml. Brain homogenate was sonicated on ice three times for 20 seconds at 80W. Samples (15 μl) were removed for total protein concentration measurements by the RC DC protein assay based on the Lowry protocol (Bio-Rad Laboratories, Hercules, CA). Sodium chloride (0.2 g, 684.5 mmol/L) was added to the extracts followed by 3 ml hexane:2-propanol (3:2 v/v) with vigorous vortexing between steps. The resulting two phases were separated by centrifugation (20,000 g 10 min at 4°C) and the upper phase was collected. The extraction procedure was repeated with 3 ml hexane:2-propanol. The collected organic solvents were combined, dried (0.3 g anhydrous sodium sulfate), filtered, and evaporated to dryness with purging nitrogen. Sample extracts were stored at −20°C until analysis.

GC/MS analysis of cholesterol, oxysterols and cholesterol precursors

Cholesterol (CH), oxysterols; 7α-hydroxycholesterol (7α-OH), 7β-hydroxycholesterol (7β-OH) 4β-hydroxycholesterol (4β-OH), β-epoxide, α-epoxide, 7-ketocholesterol (7keto-CH), 3,5,6-trihydroxy cholesterol, 24-hydroxycholesterol (24-OH) and CH precursors, lathosterol, lanosterol and desmosterol (hereafter termed Metabolites) were analyzed by GC-MS. We employed an HP Model 5890 Series II gas chromatograph (Waldbronn, Germany) fitted with an HP-5 trace analysis capillary column (0.32 mm i.d., 0.25 mm film thickness, 5% phenyl methyl silicone) and a Model 5972 mass selective detector (Waldbronn, Germany) linked to an HP ChemStation data system. Samples were first subjected to hydrolysis to convert all sterol esters into their free form. The dry residue of the extracted samples was dissolved in 0.5 ml KOH solution (20% KOH in a mixture of MeOH:DDW 70:30) and mixed for 3 h at room temperature. Two volumes of diethyl ether were added and the pH was adjusted to 5 with 0.5 ml of citric acid (20% in DDW). The upper organic phase was removed and the liquid phase was extracted with 2 ml diethyl ether. The organic layers were combined, treated with sodium sulfate and evaporated to dryness. Dried extracts were subjected to a silylating reagent N,O-bis(thrimethyl- silyl) acetamide (BSA), using 1,4-dioxane (dried on 4A molecular sieves and passed through aluminum oxide) as solvent and heated to 80°C for 60 min. The GC was operated in a splitless mode for 0.8 min and then at a split ratio of 1:1. Helium was used as the carrier gas at a flow rate of 0.656 ml/min, with 10.4 psi pressure and at a linear velocity of 31 cm/s. The MS transfer line was maintained at 280°C. The injector was set at 300°C and the detector at 330°C. The column was gradient-heated starting at 200°C, increasing to 250°C at 10°C/min, followed by 5°C/min to 300°C, and then maintained for an additional 15 min at 300°C. Samples were injected in total and single ion modes, selecting characteristic 2–4 m/z fragmentation values for each compound. A calibration curve of CH, individual oxysterols and CH precursor standards was run with each set of analyses. The recovery and reproducibility of this method was verified using standards of cholesteryl linoleate and three oxysterols – β-epoxide, 7-keto CH and 3,5,6-trihydroxycholesterol. These standards were subjected to identical hydrolysis, extraction and analysis conditions as samples to verify recovery and possible artifactual autoxidation of the sterols (Vaya et al. 2001). The m/z values for each sterol was deduced by injecting a standard of the specific sterol in total ion mode and 2–4 of the most representative fragments were selected for re-injection in single ion mode to enhance the limit of detection (which was 0.1 ppm). The specific m/z values selected for each sterol used were identical to those previously reported (Vaya et al. 2001).

HO-1 Protein Assay

Sample preparation

Approximately 50–100 mg of human frontal cortex was manually homogenized in 10 volumes of 1X extraction buffer with protease inhibitor tablets (Roche Diagnostics, Laval QC, Canada) 20–30 times at 4°C. Samples were vortexed, and centrifuged at 15,000 g at 4°C for 15 min. Supernatants were aliquoted and stored at −80°C. Lysates were assayed for protein concentration by the RC DC protein assay based on the Lowry protocol (Bio-Rad Laboratories, Hercules, CA).

ELISA

A Human HO-1 ELISA kit (Assay Designs, Inc. Ann Arbor, MI) was used to quantify HO-1 expression in human brain samples according to the manufacturer’s protocol. Briefly, samples were balanced with 1X extraction buffer to 2 mg/ml, and were individually diluted 1/10 in sample diluent. Recombinant HO-1 standard was serially diluted in sample diluent ranging from 0.78 – 25 ng/ml. One hundred μl of prepared standards and samples were loaded in duplicate wells of the anti-HO-1 immunoassay plate, incubated at room temperature for 30 min and washed 6 times with 1X washing buffer. One hundred μL of anti-human HO-1 was added to each well for 1 h, followed by 6 washes with 1X washing buffer. One hundred μL of HRP conjugate was added to each well for 30 min and washed X 6. One hundred μL of TMB substrate was added to each well and the plate was incubated at room temperature for 15 min with light shielding. One hundred μL of stop solution was added to each well and the absorbance at 450 nm was recorded using a microplate reader. HO-1 standard curves were plotted. HO-1 sample concentrations were calculated by interpolating concentrations from the standard curve, multiplying by the dilution factor, and dividing by the protein concentration, yielding a ratio of nanograms (ng) of HO-1/mg protein for each sample.

Statistical Analyses

Statistical analyses were performed using GraphPad Prism version 3.02 and Intercooled Stata 8.2 statistical software (StataCorp, College Station, TX). Demographic and clinical variables, such as age, years of education and MMSE, were described by disease state (NCI, MCI and AD). Comparisons of mean metabolite levels by disease state were examined using ANOVA. Non-parametric tests of the equality of distributions of metabolite levels across disease states were conducted using a Kruskal-Wallis (K-W) test. If an overall significant difference was found for an ANOVA or Kruskal-Wallis test of three groups (P<0.05), statistical significance levels for multiple pairwise comparisons were determined using a Bonferroni correction to the p-value equal to 0.05/3 = 0.017. Two-way associations between categorical variables were determined by a chi-square test (for large numbers) or a Fisher’s exact test (if any expected table cell count was less than 5).

The primary objectives were to survey sterols in the AD brain and to evaluate the association between HO-1 and all considered metabolites using linear regression analysis (Reg). Because there were some outlier values of HO-1, a natural log transformation for HO-1 was used to reduce the influence of these large values in regression models. Interaction terms were created to represent separate slopes for Ln HO-1 and age within each disease state. Comparison of Ln HO-1 and age slopes between disease states were conducted using a Wald test for post-estimation comparison of regression coefficients (Post-Est). Multivariable linear regression models were constructed separately for the outcomes: total cholesterol, total oxysterols and total precursors. Final multivariable models were selected based on a backward elimination procedure using covariates Ln HO-1 and available subject characteristics (disease state, gender, E4 allele, statin exposure, neuropathology score, age, education and MMSE). Correlations between metabolites were determined by non-parametric Spearman rank correlation coefficients and p-values.

Analyses between the 11 measured metabolites by disease state and subject characteristics were exploratory. Since many possible associations were examined, the p-values should be interpreted cautiously. Results are presented in the context of our research hypotheses, and both positive and negative findings are reported.

Results

Associations between HO-1 and metabolites that are presented herein were analyzed separately (stratified) by disease state; overall unstratified results were inconclusive. Associations were examined for groups of metabolites which were categorized to represent three distinct components of sterol biosynthesis: Total CH precursors (sum of lanosterol, lathosterol and desmosterol), total cholesterol (CH) and total oxysterols (sum of 7α-OH, 7β-OH, 4 β-OH, α-epoxide, β-epoxide, 24-OH, 7-keto CH). These analyses were extended by examining associations between HO-1 and individual metabolites.

a) Distribution of subject characteristics by disease state

Subject characteristics were compared across the disease states NCI, MCI and AD, using a Fisher’s exact test for categorical characteristics and a non-parametric Kruskal-Wallis test for continuous numerical characteristics (Table 1). The brain samples were carefully selected, by Religious Orders Study investigators (Z. Arvanitakis and D. Bennett), for equal distribution of gender across disease state (8 males, 9 females per group). AD and MCI subjects had a higher proportion of apolipoprotein E4 alleles compared to NCI controls, although the difference was not statistically significant. As the current study focuses on lipid neurochemistry, subjects prescribed statins were identified. Analysis of this variable revealed that although several subjects were using lipid-lowering agents, the proportions of subjects across disease state were less than 25% and were not significantly different (Exact P=0.742).

Table 1
Demographic, clinical and neuropathological characteristics of the study population.

Neuropathologic data used in analyses included Braak staging and classification of cases according to NIA-Reagan and CERAD criteria. Of these, the NIA-Reagan criteria were the most consistent, evidencing greatest neuropathology (indicated by lowest score) in AD, moderate values in MCI and least pathology in NCI (Exact P<0.05). No statistical differences were observed in subject age, years of education, post mortem time interval to autopsy, and level of Ln HO-1 expression across disease state. Mini Mental Status Exam (MMSE) scores for AD subjects were significantly lower than scores for MCI and NCI subjects (K-W P=0.0001), as expected.

b) Associations between sterols and disease state

Mean levels of CH, oxysterols and CH precursors were compared across disease state. In the majority of samples, 27-hydroxycholesterol levels were below the limit of detection of our assay and thus excluded from analysis. One-way ANOVA of individual metabolites revealed no significant differences by disease. These associations are summarized in Table 2, along with descriptive statistics of all metabolite levels. Of note, a correlation among the AD subjects of elevated total CH and diminishing MMSE scores fell just short of statistical significance (P=0.0533). If substantiated, these findings would imply a possible association between cognitive impairment and brain CH retention in AD. In addition, levels of α-epoxide in AD brain, a marker of oxidative stress (Ferderbar et al. 2007), exhibited a trend (K-W P=0.09) towards increasing concentrations with greater neuropathological burden (disease progression) as measured by Braak score (data not shown).

Table 2
Summary statistics and p-values for separate one-way ANOVAs representing comparisons between each metabolite as outcome and disease state (AD/MCI/NCI) as covariate. Total Oxysterols is equal to the sum of 7α-hydroxycholesterol (7α-OH), ...

c) Associations between age and sterols

Age is a risk factor for AD and was thus considered as a continuous variable for linear regression analysis of all metabolites. A positive association between age and total precursors was observed (Reg P<0.05) independent of disease state. Age and total oxysterols were marginally associated (Reg P=0.09), while the association between age and total cholesterol was not significant. To investigate further the association between sterols and age, we controlled the analysis for disease state by estimating different age slopes for each disease state. There were no observed differences between the age slopes within disease states for the separate outcomes: total cholesterol, total oxysterols and total CH precursors. There was a greater association between age and β-epoxide for MCI subjects relative to NCI (Post-Est P<0.05) and AD (Post-Est P=0.10) (Fig 1a). Additional analyses (Fig 1b) revealed a positive association between age and the enzymatic formation of 24-OH in NCI and MCI. However, in this association, AD subjects exhibited a decrease in 24-OH with age relative to NCI (Post-Est P<0.05). A similar relationship for the CH precursor lathosterol was observed (AD vs. NCI Post-Est P<0.005) (Fig 1c), where lathosterol also decreases with age in AD, increases with age in NCI and decreases in MCI (non-significantly relative to NCI).

Figure 1
Linear regressions of oxysterols and CH precursors (% of total cholesterol (uM)) as a function of age are depicted within disease state stratifications.

d) Associations between HO-1 and sterols

The primary objective was to examine the associations between HO-1 protein expression and all metabolites using linear regressions and disease state stratification. No significant difference in Ln HO-1 protein expression was observed amongst disease states (Table 1). In MCI, there was a significant decrease in total brain CH as Ln HO-1 increased. This relationship was not significant for the NCI and AD samples (Fig 2c). Decreased CH was also observed when comparing the slopes of NCI to AD subjects, but this did not reach statistical significance (Post-Est P=0.16). A positive association between Ln HO-1 and total oxysterols was observed in AD and was significantly different from the slope of this association in NCI (Post-Est P<0.005) (Fig 2b). Additionally, a significant association between total CH precursors and Ln HO-1 was observed in AD that was significantly different from the slope of this association in NCI (Post-Est P=0.01) (Fig 2c).

Figure 2
The regressions illustrate the differential impact of HO-1 protein levels on total oxysterols (a), total CH precursors (b) and total CH (c) in AD, MCI and NCI.

In an analysis of individual oxysterol metabolites and Ln HO-1, the influence of HO-1 expression on total oxysterols in AD was primarily driven by the positive associations of 7α-OH (P<0.05), 7β-OH (P=0.07) and β-epoxide (P=0.08), all of which have positive slopes in AD relative to those of NCI. No significant associations were observed for Ln HO-1 with respect to α-epoxide (P=0.7), 7-keto CH (P=0.13) and 24-OH (P=0.9) and 4β-OH (P=0.8) among AD subjects.

e) Metabolite-to-metabolite correlations by disease state

To determine the interrelationship between oxysterols, CH precursors and CH for disease state, non-parametric Spearman correlations (SPC) were calculated for all possible outcome combinations (Table 3). For the CH autoxidation products (non-enzymatically generated oxysterol species: 7β-OH, α-epoxide, β-epoxide, 7-keto CH), we observed significant non-parametric Spearman correlations (SPC) between α-epoxide and 7β-OH in AD (SPC= 0.639; P<0.005) and MCI (SPC=0.726; P<0.001) and no correlation for NCI (SPC=0.183; P=0.48). For oxysterols formed by enzymatic reactions (7α-OH, 24-OH), we obtained a positive correlation between 24-OH and 7α-OH in AD (SPC=0.529; P<0.05) and MCI (SPC=0.841; P<0.001), but no correlation in NCI (SPC=-0.127; P=0.62). Finally, comparing CH autoxides and enzymatic oxysterols, we observed positive correlations between β-epoxide and 24-OH for NCI (SPC=0.713; P<0.001) and MCI (SPC=0.597; P<0.01), but not for AD (SPC=0.283; P=0.27).

Table 3
Metabolite-to-metabolite interrelationships (non-parametric Spearman correlation) for disease state. 4β-OH, a housekeeping oxysterol, was included in this analysis but not depicted here. Correlation values with a magnitude greater than 0.5 were ...

f) Multivariable models for total CH, total CH precursors and total oxysterols

Multivariable models were constructed to represent three distinct components of sterol biosynthesis: Total CH precursors, total cholesterol (CH) and total oxysterols (Table 4). Because associations between Ln HO-1, age and metabolites were found when data were stratified by disease type, interaction terms were used to represent separate slopes for Ln HO-1 and age within each disease state. A graphical representation of the regression lines corresponds to the plotted lines in figure 2 when only the intercept terms and slope coefficient terms for Ln HO-1 within disease state are in the model for each outcome variable. In addition to these variables, presence of E4 allele, age and gender were also important predictors in specific models.

Table 4
Multivariable linear regression models for each of the outcomes: total CH, total CH precursors and total oxysterols. Each column represents a separate model with the following equation: Outcome level = Intercept term + Ln HO-1 coefficient* Ln HO-1 + Age ...

The best predictors of total CH content in the human brain were Ln HO-1 among MCI subjects (Reg P=0.08) and gender (Reg P=0.09); total CH was higher for men vs. women and values decreased as Ln HO-1 increased only among MCI subjects. The model for total CH precursors revealed that the latter significantly increased as Ln HO-1 protein levels increased among AD subjects (Reg P=0.01), and age and E4 allele were also minor predictors of precursor levels (0.05<Reg P<0.10). Total oxysterols also significantly increased as Ln HO-1 increased among AD subjects (Reg P=0.001) and oxysterols were lower for subjects with an E4 allele (Reg P=0.01).

Discussion

The role of CH in AD is the subject of considerable controversy and literature surveys of this field have revealed little consistency (Bjorkhem & Meaney 2004, Panza et al. 2006, Bjorkhem et al. 2006, Simons et al. 2001, Puglielli et al. 2003, Shobab et al. 2005). Several unique features were incorporated into the current experimental design in an attempt to overcome limitations inherent to prior work and derive a more direct and comprehensive understanding of deranged sterol homeostasis in AD. First, rather than focusing on select components of the CH regulatory pathway, we evaluated the cascade as a whole by assessing levels and interactions among relevant CH precursors, key oxysterol species (CH end products) and CH itself. Second, we made these determinations in affected human brain tissue in contradistinction to blood sterol/clinical correlations investigated in earlier reports. Third, the brain tissue samples were procured from the Religious Orders Study (described in Materials and Methods) permitting meticulous correlation of neural sterol concentrations with a range of salient demographic, clinical and neuropathological variables. Finally, we queried, for the first time, the impact of HO-1 protein expression on human brain sterol homeostasis, guided by novel hypotheses generated in the course of our in vitro experimentation (Vaya et al. 2007, Hascalovici et al. 2009). An initial analysis comparing concentrations of all metabolites in respective disease states (NCI, MCI and AD) did not reveal statistically significant relationships (Table 2) suggesting that ‘disease state’ may simply be too crude a stratification for lipid neurochemical analyses, or that associations differed depending on where in the course of disease the metabolites were assayed. Three multivariable models were constructed to determine if and to what extent relevant AD predictors impact the chief components of the CH regulatory pathway within the CNS, viz., total CH precursors, CH and oxysterols. In our first model, gender and disease state (MCI) emerged as the only reliable predictors of total brain CH. A second model constructed for the outcome of total oxysterols revealed that the E4 allele, increased HO-1 protein levels and disease state were robust predictors of this class of sterol metabolites. These findings are consistent with our previous observation of augmented oxysterol production in cultured rat astroglia engineered to over-express the human ho-1 gene by transient transfection (Vaya et al. 2007) at levels akin to those documented in astrocytes residing within AD-affected cerebral cortex and hippocampus (Schipper et al. 1995). Furthermore, the relationship of total brain oxysterols to the E4 allele and increased HO-1 protein levels is commensurate with a recent report by Jofre-Monseny and colleagues indicating that lipopolysaccharide induces HO-1 expression in macrophages transfected with the E4 allele, but not those expressing E3 (Jofre-Monseny et al. 2007). A third model constructed for total CH precursors supported our prediction that the latter would be impacted (augmented) by HO-1 and disease state. This prediction was based on our observation that HO-1 over-expression facilitates de novo CH biosynthesis in cultured astroglia, an event contingent upon the enhanced availability of CH precursors (Hascalovici et al. 2009).

In the current study, age, an important risk factor for AD (Tyas et al. 2001, Lindsay et al. 2002), exhibited complex interactions with brain sterol homeostasis. In an analysis of individual metabolites, we determined that 24-hydroxycholesterol (24-OH) and lathosterol (CH precursor) decrease as a function of age in AD brain, but increase in relation to age in NCI and MCI (Fig 1b,c). 24-OH is the product of an enzymatic hydroxylation of CH at the 24th carbon yielding a more hydrophilic sterol capable of traversing the blood-brain barrier (Vaya & Schipper 2007, Bjorkhem et al. 2006, Leoni et al. 2003). To examine the possibility that the observed decrease in 24-OH may be due to neuronal loss in AD and an attendant decrease in the levels and activity of CYP46A1 (cholesterol 24-hydoxylase), we standardized the levels of these sterols to mg of cellular protein (rather than total CH) and plotted 24-OH/mg protein as a function of total CH/mg protein. Disease state did not impact this relationship suggesting that the decrease in 24-OH may be the result of an increase in total free CH (likely derived from widespread myelin and cell membrane collapse) that exceeds the brain’s capacity for conversion to 24-OH. Linkages between augmented pools of free CH and degeneration of neuronal perikarya and synapses in AD brain have been previously reported (Vaya & Schipper 2007).

There is currently considerable interest in the role(s) CH may play in the etiopathogenesis of AD. CH promotes β-secretase activity (Xiong et al. 2008) and β-amyloid deposition (Burns et al. 2003) and may influence the stability of lipid rafts (Simons & Ehehalt 2002) and neurofibrillary tangles (Distl et al. 2003). Acting through these (and possibly other) mechanisms, curtailment of CH export from the aging AD brain may exacerbate the neurodegenerative process and account for the inverse relationship of brain CH and MMSE scores observed in these subjects. Sequestration of CH in aging AD brain may also be responsible for the concomitant decline in the CH precursor, lathosterol (Fig 1), a widely accepted marker of CH biosynthesis (Kempen et al. 1988), as CH inhibits the latter via complex feedback servomechanisms (Goldstein & Brown 1990). A similar phenomenon may explain the progressive diminution of brain lathosterol levels in the APP23 mouse model of AD (Lutjohann et al. 2002).

The strong association of age with β-epoxide in MCI (Fig. 1c), but not NCI or AD, may further inform current thinking concerning the role of oxidative stress in the pathogenesis of AD. β-epoxide is a metabolite of several potentially amyloidogenic sterol species derived from the autoxidation of CH (Wang et al. 2007) and a reliable oxidative stress reporter molecule (Ferderbar et al. 2007). Our findings argue that, in the course of AD, non-enzymatic oxidative modification of brain sterols is maximal in pre-clinical (MCI) stages of the illness. This formulation is compatible with earlier reports of a) increased levels of 8,12-isoiPF2α, an index of lipid peroxidation, in the CSF, plasma and urine of subjects with MCI relative to persons without cognitive impairment. (Pratico et al. 2002) and b) elevated brain 8-OHdG and nitrotyrosine immunoreactivities, markers of oxidative nucleic acid and protein damage, respectively, in very early AD which decline with progressive disease severity (Nunomura et al. 2001).

The linear associations between HO-1 protein concentrations and CH, oxysterols and CH precursors (current study) are consistent with our earlier observations in HO-1 transfected rat astroglia (Vaya et al. 2007, Hascalovici et al. 2009). In both the latter and in AD-affected human brain tissue (Fig 2), total CH decreases and oxysterols and CH precursors/biosynthesis increase in proportion to HO-1 protein levels. Together, our findings suggest that, in AD astrocytes, enhanced CO signaling resulting from HO-1-mediated degradation of endogenous heme stimulates the cholesterol biosynthetic pathway, while heme-derived iron and CO promote CH efflux via activation of the LXR. Our in vitro data indicate further that the glial iron may indirectly contribute to CH efflux by provoking formation of oxysterols, natural ligands of the LXR (ibid.). Conceivably, enhanced egress of CH from the astrocytic compartment provides essential sterols for neuronal repair and synaptogenesis (neuroplasticity) in MCI and initial stages of AD. Under the influence of HO-1, CH efflux may exceed biosynthesis such that net glial CH content is diminished (providing further stimulus for CH biosynthesis).

Correlations of oxysterol subtypes, enzymatic oxysterols and oxysterols derived from CH autoxidation were determined for all possible associations. Our analysis uncovered disease-specific changes in the associations of individual metabolites favoring a state of dys-regulated sterol homeostasis in AD and MCI relative to NCI (Table 3). Strict regulation of these pathways is likely essential for normal brain function; while enzymatically-generated oxysterols are indispensible for CH turnover in the CNS, CH autoxidation products, accruing from free radical attack on the cholesterol molecule, have neurotoxic properties (Nelson & Alkon 2005).

On the basis of the current (human) data sets, our previous in vitro work on astroglial HO-1/sterol interactions (Vaya et al. 2007, Hascalovici et al. 2009) and the available literature on the topic, we propose a model that organizes the findings in a mechanistic and testable fashion that should facilitate further investigation of sterol dys-regulation in AD and MCI: In the normal aging brain, sterol homeostasis is maintained by pathways governing baseline CH biosynthesis, CH efflux and oxysterol formation (Fig 3a). Glial HO-1 activity/expression is present at physiological levels and its influence on sterol homeostasis is minimal. In MCI and ‘compensated’ AD (Fig 3b), various pro-oxidant and inflammatory stressors (e.g. β-amyloid, hydrogen peroxide, Th1 cytokines) induce the HMOX1 gene in affected astroglia (Schipper 2004). Resulting products of heme catabolism (CO, ferrous iron) stimulate CH biosynthesis, oxysterol formation and CH efflux by the astroglial compartment. Glial CH efflux facilitates CH delivery for neuronal repair and transport of surplus sterol (as 24-hydroxycholesterol) across the blood-brain barrier. CH egress exceeds biosynthesis and CH levels in affected brain are initially unchanged or diminished. Our data suggest that a threshold may be reached in the aging AD brain whereby the ability of HO-1 to impact the cholesterol regulatory pathway is overwhelmed by excessive CH accumulation attending widespread neuronal degeneration and failure of sterol homeostatic mechanisms. In this ‘de-compensated’ AD state (Fig 3c), glial efflux pathways cannot meet demand and brain CH progressively increases. The latter, in turn, suppresses de novo CH biosynthesis and brain CH precursor levels decline. In ‘de-compensated’ AD, the aberrant CH deposits may exacerbate the neurodegenerative process by a) undergoing autoxidation to neurotoxic lipid species, b) accelerating β-amyloid deposition and c) promoting tau hyperphosphorylation and neurofibrillary tangle formation (Xiong et al. 2008).

Figure 3Figure 3Figure 3
A model for strerol dys-regulation in AD brain. (a) In the normal aging brain, sterol homeostasis is maintained by pathways governing baseline CH biosynthesis, CH efflux and oxysterol formation. Glial HO-1 expression and its influence on sterol metabolic ...

In this study, we have provided direct evidence of deranged sterol homeostasis in the brains of persons with MCI and definite sporadic AD based on a comprehensive survey of total CH, CH precursors and oxysterols. In conjunction with data derived from earlier cell culture studies, we propose a model whereby up-regulation of HO-1 favorably impacts sterol regulatory pathways in MCI and younger ‘compensated’ AD brains, whereas failure of this HO-1/sterol axis in later, ‘de-compensated’ AD exacerbates the degenerative process by facilitating neural CH deposition. Attempts to forestall deterioration to this ‘de-compensated’ state, by pharmacological or other means, may constitute a rationale neuroprotective strategy for the management of AD and possibly other aging-related neurodegenerative disorders.

Acknowledgments

The authors would like to thank Mrs. Adrienne Liberman for her assistance with graphic designs, and Ms. Jordana Delnick, Mr. Gabriel Cartman and Mr. Nathan Light for technical assistance. The authors would also like to thank Dr. Saeed Mahmood for assistance with GC-MS operation. We are indebted to the hundreds of nuns, priests, and brothers from the following groups participating in the Religious Orders Study: Archdiocesan priests of Chicago, IL, Dubuque, IA, and Milwaukee, WI; Benedictine Monks, Lisle, IL, Collegeville, MN, and St. Meinrad, IN; Benedictine Sisters of Erie, Erie, PA; Benedictine Sisters of the Sacred Heart, Lisle, IL; Capuchins, Appleton, WI; Christian Brothers, Chicago, IL, and Memphis, TN; Diocesan priests of Gary, Gary, IN; Dominicans, River Forest, IL; Felician Sisters, Chicago, IL; Franciscan Handmaids of Mary, New York, NY; Franciscans, Chicago, IL; Holy Spirit Missionary Sisters, Techny, IL; Maryknolls, Los Altos, CA, and Ossining, NY; Norbertines, DePere, WI; Oblate Sisters of Providence, Baltimore, MD; Passionists, Chicago, IL; Presentation Sisters, B.V.M., Dubuque, IA; Servites, Chicago, IL; Sinsinawa Dominican Sisters, Chicago, IL, and Sinsinawa, WI; Sisters of Charity, B.V.M., Chicago, IL, and Dubuque, IA; Sisters of the Holy Family, New Orleans, LA; Sisters of the Holy Family of Nazareth, Des Plaines, IL; Sisters of Mercy of the Americas, Chicago, IL, Aurora, IL, and Erie, PA; Sisters of St. Benedict, St. Cloud and St. Joseph, MN; Sisters of St. Casimir, Chicago, IL; Sisters of St. Francis of Mary Immaculate, Joliet, IL; Sisters of St. Joseph of LaGrange, LaGrange Park, IL; Society of Divine Word, Techny, IL; Trappists, Gethsemani, KY, and Peosta, IA; and Wheaton Franciscan Sisters, Wheaton, IL.

This study was supported by grants from Canadian Institutes of Health Research (HMS), the National Institute on Aging (USA) grants P30 AG10161 and R01 AG15819 (DAB) and K23 AG23675 (ZA) and the Fonds de la recherche en sante Quebec (JH). The results of this study were presented, in part, at the International Conference on Alzheimer’s Disease (Chicago, July 26-31, 2008).

Footnotes

Disclosures

Hyman Schipper has served as consultant to Osta Biotechnologies, Molecular Biometrics Inc., TEVA Neurosciences and Caprion Pharmaceuticals. He holds stock options in Osta and equity in Molecular Biometrics Inc. None of the authors has financial interests related to the material contained in this article.

References

  • Arca M, Natoli S, Micheletta F, et al. Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy. Free radical biology & medicine. 2007;42:698–705. [PubMed]
  • Arvanitakis Z, Schneider JA, Wilson RS, Bienias JL, Kelly JF, Evans DA, Bennett DA. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology. 2008;70:1795–1802. [PubMed]
  • Baranano DE, Snyder SH. Neural roles for heme oxygenase: contrasts to nitric oxide synthase. Proceedings of the National Academy of Sciences of the United States of America. 2001;98:10996–11002. [PubMed]
  • Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, Barnes LL, Fox JH, Bach J. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59:198–205. [PubMed]
  • Bjorkhem I, Diczfalusy U. Oxysterols: friends, foes, or just fellow passengers? Arteriosclerosis, thrombosis, and vascular biology. 2002;22:734–742. [PubMed]
  • Bjorkhem I, Heverin M, Leoni V, Meaney S, Diczfalusy U. Oxysterols and Alzheimer’s disease. Acta Neurol Scand Suppl. 2006;185:43–49. [PubMed]
  • Bjorkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arteriosclerosis, thrombosis, and vascular biology. 2004;24:806–815. [PubMed]
  • Burns M, Gaynor K, Olm V, et al. Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo. J Neurosci. 2003;23:5645–5649. [PubMed]
  • Distl R, Treiber-Held S, Albert F, Meske V, Harzer K, Ohm TG. Cholesterol storage and tau pathology in Niemann-Pick type C disease in the brain. J Pathol. 2003;200:104–111. [PubMed]
  • Dore S, Takahashi M, Ferris CD, Zakhary R, Hester LD, Guastella D, Snyder SH. Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury. Proceedings of the National Academy of Sciences of the United States of America. 1999;96:2445–2450. [PubMed]
  • Ferderbar S, Pereira EC, Apolinario E, et al. Cholesterol oxides as biomarkers of oxidative stress in type 1 and type 2 diabetes mellitus. Diabetes Metab Res Rev. 2007;23:35–42. [PubMed]
  • Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425–430. [PubMed]
  • Hascalovici JR, Song W, Vaya J, Khatib S, Fuhrman B, Aviram M, Schipper HM. Impact of heme oxygenase-1 on cholesterol synthesis, cholesterol efflux and oxysterol formation in cultured astroglia. Journal of neurochemistry. 2009;108:72–81. [PubMed]
  • Hendrie HC. Epidemiology of dementia and Alzheimer’s disease. Am J Geriatr Psychiatry. 1998;6:S3–18. [PubMed]
  • Jofre-Monseny L, Loboda A, Wagner AE, Huebbe P, Boesch-Saadatmandi C, Jozkowicz A, Minihane AM, Dulak J, Rimbach G. Effects of apoE genotype on macrophage inflammation and heme oxygenase-1 expression. Biochemical and biophysical research communications. 2007;357:319–324. [PMC free article] [PubMed]
  • Kempen HJ, Glatz JF, Gevers Leuven JA, van der Voort HA, Katan MB. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res. 1988;29:1149–1155. [PubMed]
  • Leoni V, Masterman T, Patel P, Meaney S, Diczfalusy U, Bjorkhem I. Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and blood-cerebrospinal fluid barriers. J Lipid Res. 2003;44:793–799. [PubMed]
  • Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell B, Hill GB, McDowell I. Risk factors for Alzheimer’s disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol. 2002;156:445–453. [PubMed]
  • Llesuy SF, Tomaro ML. Heme oxygenase and oxidative stress. Evidence of involvement of bilirubin as physiological protector against oxidative damage. Biochimica et biophysica acta. 1994;1223:9–14. [PubMed]
  • Lutjohann D, Brzezinka A, Barth E, Abramowski D, Staufenbiel M, von Bergmann K, Beyreuther K, Multhaup G, Bayer TA. Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain. J Lipid Res. 2002;43:1078–1085. [PubMed]
  • McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–944. [PubMed]
  • Melov S, Adlard PA, Morten K, et al. Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS ONE. 2007;2:e536. [PMC free article] [PubMed]
  • Nakagami T, Toyomura K, Kinoshita T, Morisawa S. A beneficial role of bile pigments as an endogenous tissue protector: anti-complement effects of biliverdin and conjugated bilirubin. Biochimica et biophysica acta. 1993;1158:189–193. [PubMed]
  • Nelson TJ, Alkon DL. Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide. The Journal of biological chemistry. 2005;280:7377–7387. [PubMed]
  • Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001;60:759–767. [PubMed]
  • Panza F, D’Introno A, Colacicco AM, Capurso C, Pichichero G, Capurso SA, Capurso A, Solfrizzi V. Lipid metabolism in cognitive decline and dementia. Brain Res Rev. 2006;51:275–292. [PubMed]
  • Pfrieger FW. Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes? Bioessays. 2003;25:72–78. [PubMed]
  • Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol. 2002;59:972–976. [PubMed]
  • Puglielli L, Tanzi RE, Kovacs DM. Alzheimer’s disease: the cholesterol connection. Nat Neurosci. 2003;6:345–351. [PubMed]
  • Schipper HM. Heme oxygenase expression in human central nervous system disorders. Free radical biology & medicine. 2004;37:1995–2011. [PubMed]
  • Schipper HM, Cisse S, Stopa EG. Expression of heme oxygenase-1 in the senescent and Alzheimer-diseased brain. Annals of neurology. 1995;37:758–768. [PubMed]
  • Schroepfer GJ., Jr Oxysterols: modulators of cholesterol metabolism and other processes. Physiol Rev. 2000;80:361–554. [PubMed]
  • Selkoe DJ. Alzheimer’s disease. In the beginning. Nature. 1991;354:432–433. [PubMed]
  • Shobab LA, Hsiung GY, Feldman HH. Cholesterol in Alzheimer’s disease. Lancet neurology. 2005;4:841–852. [PubMed]
  • Shoda J, Toll A, Axelson M, Pieper F, Wikvall K, Sjovall J. Formation of 7 alpha- and 7 beta-hydroxylated bile acid precursors from 27-hydroxycholesterol in human liver microsomes and mitochondria. Hepatology. 1993;17:395–403. [PubMed]
  • Simons K, Ehehalt R. Cholesterol, lipid rafts, and disease. J Clin Invest. 2002;110:597–603. [PMC free article] [PubMed]
  • Simons M, Keller P, Dichgans J, Schulz JB. Cholesterol and Alzheimer’s disease: is there a link? Neurology. 2001;57:1089–1093. [PubMed]
  • Song W, Pierce WM, Jr, Saeki Y, Redinger RN, Prough RA. Endogenous 7-oxocholesterol is an enzymatic product: characterization of 7 alpha-hydroxycholesterol dehydrogenase activity of hamster liver microsomes. Arch Biochem Biophys. 1996;328:272–282. [PubMed]
  • Tyas SL, Manfreda J, Strain LA, Montgomery PR. Risk factors for Alzheimer’s disease: a population-based, longitudinal study in Manitoba, Canada. Int J Epidemiol. 2001;30:590–597. [PubMed]
  • Vaya J, Aviram M, Mahmood S, Hayek T, Grenadir E, Hoffman A, Milo S. Selective distribution of oxysterols in atherosclerotic lesions and human plasma lipoproteins. Free radical research. 2001;34:485–497. [PubMed]
  • Vaya J, Schipper HM. Oxysterols, cholesterol homeostasis, and Alzheimer disease. Journal of neurochemistry. 2007;102:1727–1737. [PubMed]
  • Vaya J, Song W, Khatib S, Geng G, Schipper HM. Effects of heme oxygenase-1 expression on sterol homeostasis in rat astroglia. Free radical biology & medicine. 2007;42:864–871. [PubMed]
  • Wang Y, Karu K, Griffiths WJ. Analysis of neurosterols and neurosteroids by mass spectrometry. Biochimie. 2007;89:182–191. [PubMed]
  • Wilson RS, Beckett LA, Barnes LL, Schneider JA, Bach J, Evans DA, Bennett DA. Individual differences in rates of change in cognitive abilities of older persons. Psychol Aging. 2002;17:179–193. [PubMed]
  • Xiong H, Callaghan D, Jones A, et al. Cholesterol retention in Alzheimer’s brain is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiol Dis. 2008;29:422–437. [PMC free article] [PubMed]